Difference between revisions of "NF-kappa-B inhibitor alpha"
m |
m |
||
Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
− | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
Line 49: | Line 49: | ||
| | | | ||
|- | |- | ||
− | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase|*]] | [[Category:Tissue transglutaminase|*]] |
Latest revision as of 11:49, 10 March 2015
NF-kappa-B inhibitor alpha | |
---|---|
Substrate peptide name | NF-kappa-B inhibitor alpha |
Synonyms | I-kappa-B-alpha |
Determination type | In vitro |
Source | Homo sapiens |
Subcellular localization | Cytosol |
Swissprot ID | P25963 |
Reactive glutamines | Q266, Q267, Q313 |
Reactive lysines | K21, K22, K177 |
Substrate sequence | PRDGLKKERLLD
LHSILKATNYN PSTRIQQQLGQL DCVFGGQRLTL |
Structure | 1IKN |
Surface accessibility | ASAView pdf |
Disorder prediction | IUPred |
Reference | PMID:16987813 |
Notes | |